An overview of the use of anti-tuberculous drugs in Uganda and Hong Kong.
Anti-tuberculous (Anti-TB) chemotherapy in Uganda is outlined. Its pattern of use and the subsequent shortcomings have prompted the need for the present review. A collateral comparison to that of Hong Kong was run to emphasize the correlation of anti-TB chemotherapy with economic development and regional variation in the population of the two areas. Tuberculosis of the central nervous system (CNS) has a high fatality rate. In the search for a more comprehensive anti-TB dosage regimen, the difficulty in treating tuberculosis of the CNS has attracted special attention with emphasis on the fate of anti-TB drugs across the meninges. The choice of a method for drug analysis in routine therapeutic drug monitoring for a country is likewise determined by factors similar to those for the anti-TB regimen. Uganda needs an inexpensive, precise and selective method for TB treatment tailored to its financial and manpower resources.
Walubo
A
A
Department of Pharmacology, Chinese University of Hong Kong, Shatin, N.T.
Chan
K
K
Wong
C L
CL
D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005252:Fees, Pharmaceutical; D006723:Hong Kong / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D014390:Tuberculosis, Meningeal / Q000188:drug therapy* / Q000401:mortality; D014454:Uganda / Q000453:epidemiology